Last updated: March 18, 2026
CRYSVITA (burosumab) targets X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia (TIO). It is marketed by Ultragenyx Pharmaceutical. Its formulation and excipient profile influence manufacturing, stability, delivery, and market positioning.
What Are the Core Excipient Components in CRYSVITA?
CRYSVITA is supplied as a lyophilized powder for reconstitution. The excipient composition includes:
- Sucrose: Stabilizes the protein during lyophilization and storage.
- Disodium phosphate: Maintains pH stability.
- Potassium dihydrogen phosphate: Buffer component.
- Water for injection: Solvent.
The combination ensures protein stability, maintains pH, and optimizes shelf life.
How Do Excipient Choices Affect CRYSVITA's Storage and Administration?
The excipient profile influences key aspects:
Stability and Shelf Life
Sucrose protects burosumab from denaturation and aggregation during lyophilization, extending shelf life to 36 months at refrigerated conditions (2-8°C).
Reconstitution
The lyophilized powder reconstitutes in sterile water; excipients ensure consistent rehydration and infusion reliability.
Compatibility
Excipients avoid interactions with the active ingredient, minimizing immunogenicity and adverse reactions.
What Are the Commercial Implications of CRYSVITA’s Excipient Strategy?
Manufacturing Efficiency
- Lyophilization with sucrose and phosphate buffers simplifies scale-up.
- Stability reduces supply chain risks.
Intellectual Property
- Existing patents cover excipient formulations. Innovator companies secure exclusivity for specific excipient compositions to prevent generic bypass.
Market Expansion Potential
- Development of ready-to-use formulations minimizes administration time, appealing for outpatient settings.
- Alternative excipient formulations could enable subcutaneous or less invasive delivery, expanding patient access.
Regulatory Landscape
- Excipient clarity is critical for regulatory approval. The current profile complies with FDA and EMA standards.
- Future formulations with novel excipients could shorten approval timelines or allow for combination therapies.
Are There Opportunities for Excipient Innovation in CRYSVITA?
Potential areas include:
- Stabilizers: Incorporation of sugar alcohols or polymers (e.g., trehalose, PEG) could enhance stability.
- Buffer Systems: Alternative buffers (e.g., citrate) may improve pH stability and reduce osmolarity concerns.
- Vaccine-Like Delivery Systems: Lipid nanoparticles or other carriers could permit alternative routes of administration.
Such innovations could lead to different formulations that improve patient compliance, reduce manufacturing costs, or extend product life cycle.
How Can Excipient Strategies Unlock Broader Commercial Opportunities?
- Extended Patent Life: Patents covering novel excipients or formulations can provide market exclusivity.
- Differentiation: Superior stability or easier administration can differentiate the product in competitive markets.
- Cost Reduction: Optimized excipients can lower manufacturing costs, improving margin or enabling price competitiveness.
- New Indications: Custom excipients could facilitate combination drugs, expanding indications.
Key Takeaways
- CRYSVITA’s current excipient profile includes sucrose and phosphate buffers, supporting stability and shelf life.
- Excipient stability influences manufacturing, regulatory approval, and market entry strategies.
- Innovation in excipient formulation presents opportunities for extending patent protection, reducing costs, and expanding access.
- Developing novel delivery systems could broaden patient base and market share.
5 FAQs
1. Can alternative excipients improve CRYSVITA’s stability?
Yes. Incorporating stabilizers like trehalose or PEG may enhance thermal and long-term stability, but require regulatory evaluation.
2. How does excipient selection impact regulatory approval?
Regulatory agencies scrutinize excipient safety, compatibility, and manufacturing consistency. Changes can require additional testing and approval.
3. Are there opportunities to develop a liquid formulation of CRYSVITA?
Potentially. A stable liquid formulation could improve convenience, but requires extensive stability and compatibility studies.
4. Can excipient innovation extend CRYSVITA’s patent protection?
Yes. Patents on novel excipient combinations or delivery methods can prolong exclusivity periods.
5. What manufacturing challenges relate to excipients in lyophilized drugs?
Ensuring uniform reconstitution, avoiding moisture ingress, and maintaining batch-to-batch consistency are primary concerns.
References
- Ultragenyx Pharmaceutical. (2022). CRYSVITA (burosumab) prescribing information.
- European Medicines Agency. (2021). CRYSVITA (burosumab): Summary of Product Characteristics.
- Food and Drug Administration. (2022). Guidance for Industry: Chemistry, Manufacturing, and Controls Data for Biological Drugs.
- Zhang, H., et al. (2020). Stabilization strategies for lyophilized biopharmaceuticals. Journal of Pharmaceutical Sciences, 109(4), 1340-1350.
- Buxbaum, R. E., & Kollman, T. R. (2019). Lyophilized protein stability and the impact of excipients. Biotechnology Advances, 37, 107405.
(End of report)
